Cargando…

Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison

This study compared the clinical efficacy and safety of attention-deficit/hyperactivity disorder (ADHD) pharmacotherapy in children and adolescents 6–17 years of age. A systematic literature review was conducted to identify randomized controlled trials (RCTs) of pharmacologic monotherapies among chi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joseph, Alain, Ayyagari, Rajeev, Xie, Meng, Cai, Sean, Xie, Jipan, Huss, Michael, Sikirica, Vanja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532417/ https://www.ncbi.nlm.nih.gov/pubmed/28258319 http://dx.doi.org/10.1007/s00787-017-0962-6

Ejemplares similares

Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment
por: Huss, Michael, et al.
Publicado: (2016)

Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents
por: Sikirica, Vanja, et al.
Publicado: (2012)

Comparative Efficacy of Guanfacine Extended Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Applying Matching-Adjusted Indirect Comparison Methodology
por: Sikirica, Vanja, et al.
Publicado: (2013)

Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD
por: Lachaine, Jean, et al.
Publicado: (2016)

Authors’ Reply to Alatorre et al.: “Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison”
por: Erder, M. Haim, et al.
Publicado: (2013)

Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial
por: Stein, Mark A., et al.
Publicado: (2015)

Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder
por: Martinez-Raga, Jose, et al.
Publicado: (2015)

Concomitant Pharmacotherapy of Psychotropic Medications in EU Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
por: Sikirica, Vanja, et al.
Publicado: (2013)

Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder – a systematic literature review
por: Gajria, Kavita, et al.
Publicado: (2014)

Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No Pharmacotherapy
por: Schneider, Gary, et al.
Publicado: (2019)

Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study
por: Iwanami, Akira, et al.
Publicado: (2020)

Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe
por: Huss, Michael, et al.
Publicado: (2015)

Correction to: Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study
por: Iwanami, Akira, et al.
Publicado: (2020)

Attention deficits following ADEM ameliorated by guanfacine
por: Singh-Curry, Victoria, et al.
Publicado: (2010)

Pharmacokinetics of Coadministration of Guanfacine Extended Release and Methylphenidate Extended Release
por: Roesch, Benno, et al.
Publicado: (2013)

Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine
por: Joseph, Alain, et al.
Publicado: (2016)

A retrospective medical chart review of clinical outcomes in children and adolescents with attention-deficit/hyperactivity disorder treated with guanfacine extended-release in routine Canadian clinical practice
por: van Stralen, Judy, et al.
Publicado: (2021)

Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate
por: Roesch, Benno, et al.
Publicado: (2013)

Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada
por: Lachaine, Jean, et al.
Publicado: (2019)

Efficacy and safety of guanfacine extended‐release in Japanese adults with attention‐deficit/hyperactivity disorder: Exploratory post hoc subgroup analyses of a randomized, double‐blind, placebo‐controlled study
por: Naya, Noriyuki, et al.
Publicado: (2020)

Psychometric validation of the Weiss Functional Impairment Rating Scale-Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorder
por: Gajria, Kavita, et al.
Publicado: (2015)

Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control
por: Fridman, Moshe, et al.
Publicado: (2017)

Disruption of Pharmacotherapy During the Transition from Adolescence to Early Adulthood in Patients with Attention-Deficit/Hyperactivity Disorder: A Claims Database Analysis Across the USA
por: Farahbakhshian, Sepehr, et al.
Publicado: (2021)

Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adult Patients: Design, Development and Place in Therapy
por: Ota, Toyosaku, et al.
Publicado: (2021)

Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
por: Price, Maxwell Z., et al.
Publicado: (2023)

A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK
por: Zimovetz, Evelina A., et al.
Publicado: (2017)

Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

Initiation and Persistence of Pharmacotherapy for Youths with Attention Deficit Hyperactivity Disorder in Taiwan
por: Wang, Liang-Jen, et al.
Publicado: (2016)

Metabolite profiling of guanfacine in plasma and urine of healthy Japanese subjects after oral administration of guanfacine extended‐release tablets
por: Inoue, Yuji, et al.
Publicado: (2019)

Treatment Patterns among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder with or without Psychiatric or Neurologic Comorbidities in Sweden: A Retrospective Cohort Study
por: Sikirica, Vanja, et al.
Publicado: (2017)

Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents
por: Bello, Nicholas T
Publicado: (2015)

The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD)
por: Sagvolden, Terje
Publicado: (2006)

The Perception of Primary School Teachers Regarding the Pharmacotherapy of Attention Deficit Hyperactivity Disorder
por: Gregório, João, et al.
Publicado: (2021)

Preferences for Attention-Deficit/Hyperactivity Disorder (ADHD) Non-Stimulant Treatment Characteristics Among Children and Adolescents With ADHD and Their Caregivers
por: Flood, Emuella, et al.
Publicado: (2016)

Efficacy and Safety of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder
por: Childress, Ann C., et al.
Publicado: (2018)

Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder and/or Tourette's Disorder with Clonidine Extended Release
por: Joo, Sung Woo, et al.
Publicado: (2018)

Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder
por: Pliszka, Steven R., et al.
Publicado: (2017)

Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany
por: Greven, Peter, et al.
Publicado: (2016)

Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders
por: Ming, Xue, et al.
Publicado: (2011)

Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder
por: Wigal, Sharon B., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9d6q6a6hhnq988u1oprird3t25